Nurtec ODT Approval Expanded to Include Migraine Prevention
Rimegepant is an oral calcitonin gene-related peptide receptor antagonist.
Neurology
Guidelines Developed for Diagnosing, Treating Botulism
Signs and symptoms of some neurologic conditions overlap with botulism; thorough, serial neurologic exams should be conducted.
Combination Treatment Appears Beneficial for Chronic Migraine
Data analysis revealed that CGRP mAbs were discontinued more frequently than onabotulinumtoxinA (23% vs 3%).
Hizentra Dosing Guidelines Updated to Reflect New Study Findings
Hizentra is indicated for the treatment of adult patients with CIDP as maintenance therapy to prevent relapse of neuromuscular disability and impairment.
FDA Clears Novel Device for Upper Extremity Rehabilitation After Stroke
The device is available only with a prescription and may be used as part of rehabilitation therapy.
Nulibry Now Available for Molybdenum Cofactor Deficiency Type A
MoCD Type A is a rare, inborn error of metabolism caused by mutations in the MOCS1 gene that results in toxic sulfite accumulation in the brain.
FDA Rejects Pimavanserin sNDA for Dementia-Related Psychosis
The sNDA submission was supported by data from the pivotal phase 3 HARMONY study.
Nulibry Approved for Molybdenum Cofactor Deficiency Type A
Nulibry replaces missing cyclic pyranopterin monophosphate, which is needed to reduce levels of neurotoxic sulfites.
FDA Clears Q-Collar Device for Athletes
Of the 139 athletes who wore the Q-Collar, 77% showed no significant changes in the deeper tissues of the brain involved in the transmission of electrical nerve signals.
AAN: Smell Loss Can Persist for 5 Months After COVID-19
About half of those with compromised sense of smell during acute phase had not regained sense of smell at average of 150.1 days postdiagnosis
